money_istock-504240346_jansucko
jansucko / iStockphoto.com
6 February 2018Americas

Federal Circuit affirms Humira licence decision

Yesterday, the US Court of Appeals for the Federal Circuit backed a lower court’s decision to dismiss a declaratory judgment lawsuit filed by AbbVie over its drug Humira (adalimumab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
29 September 2017   AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
9 February 2021   The US Court of Appeals for the Federal Circuit has upheld a decision by a district court that an inventor cannot further extend his shoulder surgery patent after already being granted a term adjustment period by the US Patent and Trademark Office.

More on this story

Americas
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
29 September 2017   AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
9 February 2021   The US Court of Appeals for the Federal Circuit has upheld a decision by a district court that an inventor cannot further extend his shoulder surgery patent after already being granted a term adjustment period by the US Patent and Trademark Office.

More on this story

Americas
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
29 September 2017   AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
9 February 2021   The US Court of Appeals for the Federal Circuit has upheld a decision by a district court that an inventor cannot further extend his shoulder surgery patent after already being granted a term adjustment period by the US Patent and Trademark Office.